Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Biologics Fermentation Capacity Market Size, Share, Trends & Forecast Analysis - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering.
The global biologics fermentation capacity market is projected to reach $32.4 billion by 2036, expanding at a CAGR of 12.6% from 2026 to 2036. Market growth is being driven by a record biologics pipeline, accelerating adoption of single-use and modular bioprocessing technologies, and government-backed initiatives to reshore domestic biomanufacturing capacity.
Regulatory approvals are also strengthening demand for biologics manufacturing infrastructure. The FDA's Center for Biologics Evaluation and Research approved 24 new Biologics License Applications in 2024, including a record 13 new monoclonal antibodies. Continued expansion of bioprocessing platforms across laboratory, clinical, and commercial production scales is expected to create significant opportunities for equipment manufacturers, technology providers, and contract development and manufacturing organizations.
The report includes historical market data for 2025, estimates for 2026, and forecasts through 2036. It analyzes the biologics fermentation capacity market by system type, scale of operation, mode of operation, cell/organism type, application, end user, and geography.
Single-use and hybrid bioreactor systems support capacity expansion
Single-Use Bioreactor Systems are expected to account for the largest share of installed capacity additions through most of the forecast period. Their lower capital requirements and shorter commissioning timelines provide advantages over conventional stainless-steel facilities. Hybrid Systems are projected to be the fastest-growing system category as commercial biologics manufacturers combine single-use flexibility with stainless-steel production scale to balance rapid capacity deployment and high-volume manufacturing economics.
Recent industry activity reflects this transition. Thermo Fisher Scientific introduced its 5-liter DynaDrive single-use bioreactor in February 2026 for small-scale, GMP-ready bioprocessing. Cytiva expanded its Xcellerex platform in March 2025 with 500-liter and 2,000-liter single-use systems. FUJIFILM Diosynth Biotechnologies is also expanding its Hillerod, Denmark facility to include twelve 20,000-liter mammalian cell bioreactors and integrated fill-finish capability, representing one of Europe's largest biologics drug substance capacity investments.
Regional biologics fermentation capacity market outlook
North America and Europe together account for the largest market revenue share in 2026, supported by established CDMO networks, advanced biomanufacturing infrastructure, and high regulatory approval volumes. Asia-Pacific is expected to record the fastest CAGR through 2036, driven by major capacity investments in China and South Korea and government incentives supporting bulk drug and biopharmaceutical production in India.
India's Department of Pharmaceuticals' Production Linked Incentive Scheme for Bulk Drugs has a financial outlay of ?6,940 crore and requires minimum domestic value addition of 90% for fermentation-based products. This policy is expected to strengthen regional supply chains and encourage investment in domestic fermentation capacity.
Government support is reinforcing market development in other regions. Since its 2017 launch, the U.S. National Institute for Innovation in Manufacturing Biopharmaceuticals has awarded more than $111 million across over 120 biopharmaceutical manufacturing technology and workforce projects. In the European Union, the European Commission proposed the European Biotech Act on December 16, 2025, following the Critical Medicines Act of March 2025. These initiatives seek to expand EU biomanufacturing through fast-tracked permitting and targeted financial assistance.
Competitive landscape
Key companies operating in the biologics fermentation capacity market include Sartorius AG, Danaher Corporation/Cytiva, Thermo Fisher Scientific Inc., Merck KGaA, Eppendorf SE, ABEC, Inc., Getinge AB, Tofflon Science and Technology Co., Ltd., GEA Group Aktiengesellschaft, Pierre Guerin, ZETA GmbH, Bioengineering AG, INFORS HT, PBS Biotech, Inc., bbi-biotech GmbH, and Solaris Biotech Solutions S.r.l.
Key questions addressed in the report
- What revenue does the global biologics fermentation capacity market currently generate, and how quickly will demand grow through 2036?
- Which market drivers, constraints, and investment opportunities are shaping regional and country-level growth?
- Which system types, operating scales, production modes, cell/organism types, applications, and end users offer the strongest commercial potential?
- Which regions and countries provide the most significant growth opportunities for established manufacturers and new market entrants?
- Who are the leading biologics fermentation capacity market participants, and what products and platforms do they offer?
- How are recent product launches, facility expansions, policy initiatives, and strategic developments influencing market competition?
For more information about this report visit https://www.researchandmarkets.com/r/jkxtyl
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
